CXCR2 and breast carcinoma: Reparixin ability to inhibit stemness (evaluated by stemness marker expression and tumorsphere formation) and epithelial-mesenchymal transition (EMT) (evaluated at both the biochemical and functional level) of thyroid cancer was shown to be dependent, different than in breast cancer (9), on its activity on both CXCR1 and CXCR2 (13).